Oral oncolytics are relatively new to the field of cancer therapy. However, they now make up about 25% of the oncology market and their use is continually expanding. The current insurance system is not efficiently equipped to handle their rapid entry into the market.
Under the rule, individuals associated with security mishaps will become personally liable for their organization’s transgressions
The only predictable aspect of the influenza season is its unpredictability, according to experts.
More than a third of young people believe prescription stimulant abuse is a big problem among their peers, according to a new survey.
Approximately 90,000 Americans die every year as a result of kidney disease. This disease produces no symptoms until it is in the advanced stages, so people in the early stages are not likely to know they have it unless they are tested.
A severe decline in the use of estrogen therapy (ET) due to misunderstanding the findings of the Women’s Health Initiative (WHI) Estrogen Plus Progestin Trial has particularly affected hysterectomized women in their 50s, leading to excess mortality, according to a study published online in the American Journal of Public Health.
Meanwhile, the data collected isn't exactly in the right format for secondary use
Partners provide education and boots on the ground to improve health and attract members
Financial incentives will be linked to comprehensive care which includes the mind and body
CMS has increased the number of telehealth services it will reimburse under Medicare
State-level data shows potential cost savings when patients follow regimens
Provider relationships are essential to help patients self-manage clinical risks
MCOs are looking at each segment separately to assess opportunities for small business
Modernize delivery models and help PCPs do more now and in the future
The Comprehensive Primary Care Initiative expects high performers to up their game with technology, data sharing and quality milestones
CDC defines risk factors
WellPoint's RBP model puts market forces to work
A combination of diabetes, hypertension and dyslipidemia is the telltale sign of high risk
CoOportunity offers narrow- and tiered-network products, but don't call them HMOs
New OIG report reveals dieticians and massage therapists prescribing drugs and says plans have obligation to verify claims
Physicians have yet to master the implications of genetic test and their relationship to treatment, while plans await outcome evidence
A recent Supreme Court Decision underscores the necessity of counsel reviewing the dispute resolution terms in health plan contracts with providers
Plans have to promote the value of health coverage to overcome the noise about rate shock
FDA sent out a MedWatch warning, on July 12, 2013, after Medtronic recalled its MiniMed Paradigm insulin infusion sets.
A new retrospective case-control study among patients with chronic obstructive pulmonary disease (COPD) found a 30% decreased risk of COPD exacerbation with any statin use.
Patients taking the new generation of oral anticoagulants (nOACs) are associated with a significantly higher risk of gastrointestinal bleeding (GIB), according to a new study.
FDA advisers recommended in early June the easing of restrictions on the diabetes drug rosiglitazone (Avandia, GlaxoSmithKline), following an independent re-examination of GSK’s RECORD study conducted by Duke Clinical Research Institute.
Telmisartan and valsartan, used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke, or heart failure, according to a study published on the Canadian Medical Association Journal.
The Institute for Safe Medication Practices (ISMP) continues to receive reports of dose measurement confusion with HumuLIN R U-500 concentrated insulin injection, according to a recent safety alert from the agency.
